BioNTech's Founder Handoff: The mRNA Story Is Now an ADC/Lung-Cancer Bet
A guidance raise built on BMS collaboration revenue masks a quiet reallocation away from mRNA cancer vaccines and toward a binary gotistobart readout.
BNTX · Earnings Call · 2026-11-03
The last founder-era call was not a growth quarter
BioNTech's third quarter was a handoff, not an inflection. Revenue slipped to €1.3 billion from €1.5 billion a year ago, and nine-month revenue fell to €1.5 billion from €2.0 billion, with management pinning the decline on lower COVID-19 vaccine demand. The headline raise was real but technical: “Our updated 2026 financial revenue guidance is now EUR 1.7 billion to EUR 1.9 billion.” — Ramón Zapata, Chief Financial Officer · 2026-11-03 That midpoint lift leans on €613 million of BMS collaboration revenue recognized in the quarter, not on a recovering COVID franchise. It is the balance sheet, €16.2 billion in cash and securities, plus roughly 5 million shares repurchased since June, that lets the company keep funding late-stage trials while the top line shrinks. The bigger change is human: Uğur Şahin and Özlem Türeci presided over their last earnings call, with Guido Oelkers taking over as CEO by 1 February at the latest. The new company chatter that animated prior calls has cooled into optionality: “discussions regarding Uğur and Özlem's new company and potential contributions from BioNTech remain ongoing... optional for both parties and not a necessity.” — Ramón Zapata, Chief Financial Officer · 2026-11-03 In March, management was still framing the NewCo as a rights-and-mRNA-technology contribution, not cash; now the language is more guarded. That matters because the founder transition overlaps with a pipeline transition.Gotistobart is the near-term binary
The cleanest catalyst sits in non small cell lung cancer, specifically squamous non-small cell disease after platinum and checkpoint exposure. Updated data from the non-pivotal stage showed “median overall survival was 18.5 months with gotistobart versus 10 months with docetaxel, with a hazard ratio of 0.56.” — Özlem Türeci, Co-Founder and Chief Medical Officer · 2026-11-03 That is a 44% reduction in risk of death in a setting where chemotherapy has been the standard of care for a decade. Annemarie Hanekamp sized the commercial pool at roughly 55,000 second-line squamous patients in the G7 by 2030. But the first pivotal interim is due before year-end, and Özlem deliberately lowered expectations: “the first one is early, so even though we are excited, we will not be disappointed if we cannot see a clear signal.” — Özlem Türeci, Co-Founder and Chief Medical Officer · 2026-11-03 That is the right way to frame a binary event. If the IDMC signals a clear benefit, BioNTech has a differentiated monotherapy in a large underserved niche. If not, the story shifts entirely to pumitamig and the ADCs.The combination engine is the real growth story — and it is not near-term
Pumitamig, the PD-L1/VEGF bispecific partnered with BMS, is the backbone. BioNTech expects seven global pivotal studies by year-end, but the readout calendar is back-end loaded: first-line TNBC China data in 2027, ROSETTA Lung-02 and Lung-01 around 2029, then RCC, CRC and HCC. The most interesting recent data is in small cell lung cancer, where combination with pumitamig and Alpha D, the B7-H3 ADC, produced a 92% overall response rate in first line, 76% in second line and 52% in third line and later, with a 2.9% ILD rate. That is company-specific evidence, not sector boilerplate. In triple-negative breast cancer, ROSETTA Breast-01 is being adapted to replace chemotherapy with a TROP2-directed antibody drug conjugate after Gilead agreed to supply sacituzumab govitecan; the trial would become the first global phase III of pumitamig plus an ADC, pending regulators. This is the version of BioNTech that could become a multi-product oncology company. It is also the version that requires patience. Uğur said in August: “In 2027, we expect that we will have identified the winners and engage into several Phase III clinical trials...” — Ugur Sahin, Co-Founder and Chief Executive Officer · 2026-08-04 The strategy has not changed; the timing has simply moved closer to the point where the market will demand proof.The mRNA retreat is the real change
Here is the tension. mRNA cancer immunotherapy remains a stated pillar, but the financial architecture around it is being de-risked. BNT113 missed its first dual primary endpoint of PFS in HPV16-positive head and neck cancer;The autogene cevumeran phase II trial in colorectal cancer was discontinued with Genentech after an OS imbalance. And BioNTech exercised an option to shift future R&D costs for the Roche/Genentech mRNA program to the partner, moving from 50/50 cost-profit sharing to royalty-based economics. Ramón called it “a capital allocation decision” — Ramón Zapata, Chief Financial Officer · 2026-11-03 and insisted it was not a lack of commitment. But compare that with March: “there is no split of BioNTech's core mRNA capabilities. Our strategy and pipeline remains unchanged.” — Ramón Zapata-Gomez, Chief Financial Officer · 2026-03-10 The strategy may be unchanged on paper, but the funding and risk-sharing have changed. Then there is T-Pam: the HER2 ADC met its phase III primary endpoint in HER2-low breast cancer, but with a “statistically significant yet modest improvement in progression-free survival” — Özlem Türeci, Co-Founder and Chief Medical Officer · 2026-11-03, plus a higher ILD rate and severe/fatal cases in a small proportion. Management is discussing the totality of data with DualityBio and still plans a BLA. That is not a clean win; it is a reminder that the ADC portfolio has binary risk too.While the trial did not meet its first dual primary endpoint of progression-free survival, it is continuing as planned to assess the second dual primary endpoint of overall survival.